We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Glioblastoma Driver Mutations Appear Long Before Diagnosis

By LabMedica International staff writers
Posted on 03 Apr 2019
Print article
Image: A diagram of evolutionary trajectories of IDH-WT glioblastomas revealing a common path of early tumorigenesis instigated years ahead of initial diagnosis (Photo courtesy of German Cancer Research Center).
Image: A diagram of evolutionary trajectories of IDH-WT glioblastomas revealing a common path of early tumorigenesis instigated years ahead of initial diagnosis (Photo courtesy of German Cancer Research Center).
Glioblastomas are the most common high-grade (cancerous) primary brain tumor in adults. They can also occur, rarely, in children. Glioblastomas belong to a group of brain tumors known as gliomas, as they grow from a type of brain cell called a glial cell.

Diverse glioblastoma (GBM) tumors falling into several distinct methylation-based subgroups tend to share early driver mutations, which appear to have arisen long before individuals' initial GBM diagnoses and influence genetic features found in the tumors present at disease recurrence.

Scientists at the German Cancer Research Center (Heidelberg, Germany) and their colleagues performed whole-genome sequencing on tumor-matched blood sample controls from 21 GBM patients, along with RNA sequencing on primary and recurrent tumor samples. They also considered pairs of primary and recurrent tumors from 43 patients with IDH-wild type GBM that were profiled with targeted sequencing on 50 glioma-related genes, and used Illumina BeadChip arrays to assess DNA methylation levels across tumor samples from both groups.

The team found that by integrating these molecular data in phylogenetic and tumor growth, mutation, and evolution modeling, they were able to track down apparent initiating mutations involving chromosome 7 gains or chromosome 9 and 10 losses that appeared an estimated two to seven years before the patients' GBM diagnoses, along with mutations affecting the telomerase reverse transcriptase (TERT) promoter that appeared to mark tumor transitions to a rapid growth phase.

The authors suggested that their findings imply that standard therapy exerted little selective pressure on most recurrent tumors since the vast majority of driver mutations were acquired prior to initial diagnosis and only few drivers were acquired after initial treatment. Relapsed tumors acquired no stereotypical pattern of mutations and typically regrew from oligoclonal origins, suggesting sparse selective pressure by therapeutic measures. The study was published on March 21, 2019, in the journal Cancer Cell.

Related Links:
German Cancer Research Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.